Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A in Relapsed and Refractory Acute B-cell Leukemia
NCT05350787Phase 1Completed
- Sponsor
- Zhejiang University
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of thiscart19a in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Zhejiang University. Primary endpoints: Dose Limited Toxicity at 28 days and Treatment-Emergent Adverse Events up to 2 years. Started Mar 2022; status: completed.
02
Drugs
thiscart19a
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05350787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350787.